[go: up one dir, main page]

MX2013009362A - Anticuerpo contra el csf-1r. - Google Patents

Anticuerpo contra el csf-1r.

Info

Publication number
MX2013009362A
MX2013009362A MX2013009362A MX2013009362A MX2013009362A MX 2013009362 A MX2013009362 A MX 2013009362A MX 2013009362 A MX2013009362 A MX 2013009362A MX 2013009362 A MX2013009362 A MX 2013009362A MX 2013009362 A MX2013009362 A MX 2013009362A
Authority
MX
Mexico
Prior art keywords
csf
antibody against
compositions
antibodies
treatment
Prior art date
Application number
MX2013009362A
Other languages
English (en)
Other versions
MX347020B (es
Inventor
Helene Haegel
Christine Thioudellet
Michel Geist
Benoit Grellier
Jean-Baptiste Marchand
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of MX2013009362A publication Critical patent/MX2013009362A/es
Publication of MX347020B publication Critical patent/MX347020B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos específicos para el CSF-1R, composiciones que comprenden los anticuerpos y métodos de tratamiento que utilizan dichas composiciones.
MX2013009362A 2011-02-14 2012-02-07 Anticuerpo contra el csf-1r. MX347020B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/026,944 US8470977B2 (en) 2008-03-14 2011-02-14 Antibody against the CSF-1R
PCT/EP2012/052043 WO2012110360A1 (en) 2011-02-14 2012-02-07 Antibody against the csf-1r

Publications (2)

Publication Number Publication Date
MX2013009362A true MX2013009362A (es) 2014-04-25
MX347020B MX347020B (es) 2017-04-06

Family

ID=45808764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009362A MX347020B (es) 2011-02-14 2012-02-07 Anticuerpo contra el csf-1r.

Country Status (17)

Country Link
US (3) US8470977B2 (es)
EP (1) EP2675826B1 (es)
JP (1) JP5996558B2 (es)
KR (1) KR101920946B1 (es)
CN (2) CN103476794B (es)
AU (1) AU2012217303B2 (es)
BR (1) BR112013020500A8 (es)
CA (1) CA2825243A1 (es)
DK (1) DK2675826T3 (es)
ES (1) ES2654551T3 (es)
HU (1) HUE035617T2 (es)
IL (1) IL227078A (es)
MX (1) MX347020B (es)
RU (1) RU2621859C2 (es)
SG (1) SG191899A1 (es)
WO (1) WO2012110360A1 (es)
ZA (1) ZA201306869B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
NZ587830A (en) 2008-03-14 2012-08-31 Transgene Sa Antibody against the colony-stimulating factor-1 receptor (CSF-1R)
RU2565541C2 (ru) 2009-12-10 2015-10-20 Ф.Хоффманн-Ля Рош Аг Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение
US9221910B2 (en) 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN107011438B (zh) 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
ES2618828T3 (es) 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
RU2639553C2 (ru) * 2011-10-21 2017-12-21 Трансжене Са Модуляция активации макрофагов
JP6184965B2 (ja) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI713436B (zh) 2012-08-31 2020-12-21 美商戊瑞治療有限公司 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
TWI539961B (zh) 2012-11-09 2016-07-01 轉殖基因公司 單核球或其前驅細胞分化之調節
CA2907973A1 (en) 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015200089A1 (en) 2014-06-23 2015-12-30 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA2955084C (en) 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
CN120555373A (zh) 2014-07-16 2025-08-29 特兰斯吉恩股份有限公司 用于表达免疫检查点调节因子的溶瘤病毒
HRP20210440T1 (hr) 2014-10-29 2021-04-30 Five Prime Therapeutics, Inc. Kombinirana terapija za rak
SG11201704792UA (en) 2014-12-22 2017-07-28 Five Prime Therapeutics Inc Anti-csf1r antibodies for treating pvns
WO2016128542A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
HUE053903T2 (hu) 2015-04-13 2021-07-28 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
KR102613528B1 (ko) * 2015-04-28 2023-12-12 미쓰비시 타나베 파마 코퍼레이션 RGMa 결합 단백질 및 그 사용
EP3303390A1 (en) * 2015-05-27 2018-04-11 UCB Biopharma SPRL Method for the treatment of neurological disease
KR20240064051A (ko) * 2015-09-16 2024-05-10 아블렉시스, 엘엘씨 항-cd115 항체
WO2017217793A1 (en) 2016-06-16 2017-12-21 Farmhannong Co., Ltd. Methods and compositions for conferring and/or enhancing herbicide tolerance using protoporphyrinogen oxidase or variant thereof
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
CN109476719B (zh) 2016-07-05 2025-12-05 伊班绰斯有限责任公司 抑制肿瘤血管生成的含vegf深度阻断剂的癌症治疗组合物及其制备方法
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN110121360A (zh) * 2017-01-10 2019-08-13 杨慕华 治疗癌症转移的方法及其组合物
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
CN113301960B (zh) * 2018-12-13 2025-06-03 财团法人生物技术开发中心 抗人类csf-1r抗体和其用途
AU2020283742A1 (en) 2019-05-24 2021-09-16 Elixiron Immunotherapeutics (hong Kong) Limited Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof
JP7712917B2 (ja) 2019-09-26 2025-07-24 エフ． ホフマン－ラ ロシュ アーゲー 抗ｃｓｆ－１ｒ抗体
RU2751249C1 (ru) * 2020-10-28 2021-07-12 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с csf-1r
CN114907489A (zh) * 2022-04-24 2022-08-16 首都医科大学附属北京天坛医院 一种可诱导嵌合抗原受体及其应用
FR3160186A1 (fr) * 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59113A (en) * 1866-10-23 Improvement in horse-rakes
US317403A (en) * 1885-05-05 Seal-lock for car-doors
US245471A (en) * 1881-08-09 fabwell
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH0517367A (ja) 1991-07-08 1993-01-26 Green Cross Corp:The 骨粗鬆症治療剤
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
AU682854B2 (en) 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
DE50002293D1 (de) 1999-10-28 2003-06-26 Hofbauer Reinhold Verwendung von csf-1-inhibitoren
EP1683807A1 (fr) 2002-01-03 2006-07-26 Transgene S.A. Produits de combinaison utilisable dans le cadre d'un traitement antitumoral comprenant un anticoprs capable d'inhiber l'activité de CSF-1
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
NZ548785A (en) 2004-01-07 2011-08-26 Novartis Vaccines & Diagnostic M-CSF-Specific monoclonal antibody and uses thereof
ES2364147T3 (es) 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
SI2188313T1 (en) 2007-08-21 2018-04-30 Amgen, Inc. HUMAN C-FMS ANTIGEN TRANSFER PROTEIN
NZ587830A (en) * 2008-03-14 2012-08-31 Transgene Sa Antibody against the colony-stimulating factor-1 receptor (CSF-1R)
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
RU2639553C2 (ru) * 2011-10-21 2017-12-21 Трансжене Са Модуляция активации макрофагов
TWI539961B (zh) * 2012-11-09 2016-07-01 轉殖基因公司 單核球或其前驅細胞分化之調節

Also Published As

Publication number Publication date
CN104140467B (zh) 2017-05-31
US9428584B2 (en) 2016-08-30
JP2014506572A (ja) 2014-03-17
CA2825243A1 (en) 2012-08-23
BR112013020500A8 (pt) 2018-01-09
ES2654551T3 (es) 2018-02-14
JP5996558B2 (ja) 2016-09-21
KR101920946B1 (ko) 2018-11-21
CN103476794A (zh) 2013-12-25
EP2675826A1 (en) 2013-12-25
CN103476794B (zh) 2017-05-03
AU2012217303B2 (en) 2016-10-20
BR112013020500A2 (pt) 2016-10-18
DK2675826T3 (en) 2018-01-22
IL227078A (en) 2017-06-29
ZA201306869B (en) 2014-05-28
KR20140032992A (ko) 2014-03-17
US20130289250A1 (en) 2013-10-31
SG191899A1 (en) 2013-08-30
HUE035617T2 (en) 2018-05-28
US9982055B2 (en) 2018-05-29
US20110178278A1 (en) 2011-07-21
RU2013141956A (ru) 2015-03-27
RU2621859C2 (ru) 2017-06-07
WO2012110360A1 (en) 2012-08-23
NZ612038A (en) 2014-09-26
MX347020B (es) 2017-04-06
AU2012217303A1 (en) 2013-07-11
CN104140467A (zh) 2014-11-12
US20170002081A1 (en) 2017-01-05
US8470977B2 (en) 2013-06-25
HK1203976A1 (en) 2015-11-06
EP2675826B1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
MX347020B (es) Anticuerpo contra el csf-1r.
CY1122278T1 (el) Αντι il-36r αντισωματα
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
NZ707086A (en) Anti-cd40 antibodies and methods of use
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
WO2013119716A8 (en) Compositions and methods for using csf1r inhibitors
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
TN2012000462A1 (en) Anti-cd40 antibodies
PH12017500864A1 (en) Anti-notch1 antibodies
PH12013500810B1 (en) Anti-il-23 antibodies
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
MX367661B (es) Anticuerpos anti-baff novedosos.
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2014000531A (es) Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
AR123070A2 (es) Anticuerpos anti-il-23
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
FG Grant or registration